Meningeal tumor
Also known as: Meninges, Meningeal, Meninx, Spinal
Methodology & AI Transparency ⓘ
Meningeal tumor Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Cancer, Oncology & Supportive Care practice, Meningeal tumor (also termed Meninges or Meningeal) (ICD-10 C70.9) is stratified through immunohistochemistry [Meningeal tumor C70.9], pairing targeted symptom control with longitudinal Pathology / Molecular in Meningeal tumor (C70.9: Genomic Staging) surveillance.
- 2 Real-world patient consensus: Synonyms for Meningeal tumor (C70.9): Meninges, Meningeal, Meninx (Cancer & Oncology).
- 3 Typical cash cost range: Clinicians assessing Meningeal tumor focus on angiogenesis [Meningeal tumor C70.9] and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Meningeal tumor: Comprehensive Metabolic & in Meningeal tumor (C70.9: Organ Function Panel) (Preserved renal/hepatic clearance (C70.9)) and Pathology / Molecular in Meningeal tumor (C70.9: Genomic Staging).
Ask our AI Specialists anything about Meningeal tumor
What Is Meningeal tumor?
Within Cancer, Oncology & Supportive Care practice, Meningeal tumor (also termed Meninges or Meningeal) (ICD-10 C70.9) is stratified through immunohistochemistry [Meningeal tumor C70.9], pairing targeted symptom control with longitudinal Pathology / Molecular in Meningeal tumor (C70.9: Genomic Staging) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Meningeal tumor (ICD-10 C70.9) is driven by angiogenesis [Meningeal tumor C70.9]; specialists in Cancer, Oncology & Supportive Care monitor Pathology / Molecular in Meningeal tumor (C70.9: Genomic Staging) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Meningeal tumor (C70.9): abnormality detected early in Meningeal tumor (C70.9: on age-appropriate screening)
- • Secondary Meningeal tumor clinical sign: persistent painless lump, in Meningeal tumor (C70.9: non-healing ulcer/mole change,)
- • Symptom flares in Meningeal tumor correlating with Comprehensive Metabolic & in Meningeal tumor (C70.9: Organ Function Panel) deviation outside Preserved renal/hepatic clearance (C70.9)
- • Functional cancer & oncology impact requiring immunohistochemistry [Meningeal tumor C70.9] evaluation (C70.9)
Meningeal tumor Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C70.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NLM Clinical Tables |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Meningeal tumor (C70.9: Organ Function Panel) | Preserved renal/hepatic clearance (C70.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Meningeal tumor (C70.9: Genomic Staging) | Guideline-concordant surveillance (C70.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Meningeal tumor (C70.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C70.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Meningeal tumor
Treatment selection for Meningeal tumor depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Meningeal tumor)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid: What a 406-Participant Study Found There was no significant difference between treatments in secondary efficacy endpoints, reflecting a lack of clinical response. Leukemia research • 2024-05-15 • Phase III Randomized Trial | N = 406 | 93/100 | PMID 38499457 ↗ |
| Can This Approach Help? Inside the Latest Research on Discontinuation of the gold-standard blind, compared against a dummy pill XXL was a compared against a dummy pill (placebo) phase 3 evaluating cetuximab-radiotherapy and xevinapant (IAP inhibitor) in locally advanced squamous cell carcinoma of the head and neck, ineligible for cisplatin (Unfit). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2026-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41903611 ↗ |
| New Insights on CtDNA guiding adjuvant immunotherapy in urothelial: What a 581-Participant Study Found These data suggest that adjuvant atezolizumab may be associated with improved outcomes compared with observation in patients who are positive for ctDNA and who are at a high risk of relapse. Nature • 2021-07-15 • Phase III Randomized Trial | N = 581 | 87/100 | PMID 34135506 ↗ |
| Can This Approach Help? Inside the Latest Research on Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of SC rituximab improves PFS for patients with low-tumor burden FL when used in induction followed by short maintenance. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2023-07-01 • Phase III Randomized Trial | N = 100 | 82/100 | PMID 37071836 ↗ |
| Can This Approach Help? Inside the Latest Research on Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. This final analysis of the TROIKA trial further confirms the comparable real-world benefits and safety of HD201 and trastuzumab. BMC cancer • 2023-01-31 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 36721174 ↗ |
Meningeal tumor Patient Community & “People Like Me” Threads
Filter Meningeal tumor community threads and patient logs by age, biological sex, dosage, and treatment duration.